Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II，Multicenter, Open-Label, Study of a Novel Bruton's Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients With B-Cell Malignancies

NCT04014205 is registered in ClinicalTrials.gov with Beijing InnoCare Pharma Tech Co., Ltd. as lead sponsor.

NCT NCT04014205
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04014205 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II，Multicenter, Open-Label, Study of a Novel Bruton's Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients With B-Cell Malignancies
Lead sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 18, 2019
Completion date
June 30, 2026
Enrollment
81 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

part 1：r/r b-cell malignancies, part 2：b-cell malignancies